Curis, Inc.

507 articles about Curis, Inc.

• Curis to Present at Upcoming Healthcare Conferences - Jan 20, 2022

  1/20/2022

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer, will participate in the following upcoming conferences:

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 07, 2022

  1/7/2022

  Curis, Inc. announced that on January 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 224,700 shares of Curis common stock to eleven new employees, with a grant date of January 3, 2022.

• Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy

  1/6/2022

  Curis, Inc. today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948.

• Curis to Present at H.C. Wainwright BioConnect Conference

  1/3/2022

  Curis, Inc. today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference.

• Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

  1/3/2022

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of three new executives to its management team.

• Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF

  12/15/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has been selected for addition to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF.

• Curis Appoints John A. Hohneker, M.D. To Board Of Directors

  12/6/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of John A. Hohneker, M.D. to its Board of Directors.

• Curis Reports Third Quarter 2021 Financial Results and Business Update

  11/9/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the third quarter ended September 30, 2021 and provided business updates.

• Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

  11/9/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical data for CI-8993, a first-in-class monoclonal antibody VISTA antagonist, at the Society for Immunotherapy of Cancer's 36th Annual Meeting.

• Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

  11/8/2021

  Curis, Inc. (NASDAQ: CRIS), today announced that the first patient has been dosed in the combination therapy portion of the Phase 1/2 clinical study evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).

• Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021

  11/2/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its third quarter 2021 financial results on Tuesday, November 9, 2021, after the close of U.S. markets.

• Curis to Present at Upcoming Investor Conferences - Nov 02, 2021

  11/2/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that Curis management will participate in virtual fireside chats and panels at the following upcoming conferences in November and December.

• Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics

  10/7/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced two poster presentations with new preclinical data for CA-4948, a first-in-class small molecule IRAK4 inhibitor, at the AACR-NCI-EORTC Virtual Conference.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Oct 06, 2021

  10/6/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that on October 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 106,350 shares of Curis common stock to five new employees, with a grant date of October 1, 2021.

• Curis to Present at Upcoming Healthcare Conferences in September 2021

  9/2/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the following upcoming conferences.

• Curis Reports Second Quarter 2021 Financial Results

  8/3/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the second quarter ended June 30, 2021.

• Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021

  7/27/2021

  Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2021 financial results on Tuesday, August 3, 2021, after the close of US markets.

• Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - July 07, 2021

  7/7/2021

  Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that on July 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 259,550 shares of Curis common stock to fifteen new employees, with a grant date of July 1, 2021.

• Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes

  6/25/2021

  Curis, Inc. today announced that it will be added to the Russell 2000®, 3000® and Microcap® indexes at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 4, 2021.

• Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

  6/11/2021

  Curis, Inc. announced updated data from its ongoing Phase 1/2 open-label, single arm, dose escalation and expansion trial of CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia or high-risk myelodysplastic syndromes at the European Hematology Association 2021 Virtual Congress.